Targeting tumour necrosis factor alleviates signs and symptoms of inflammatory osteoarthritis of the knee

Table 2 WOMAC subscales in patients with inflammatory osteoarthritis of the knee who received open-label adalimumab

	Baseline	4 weeks	8 weeks	12 weeks	Pvalue^a	22 weeks^b
WOMAC pain	60.8 (17.5)	49.6 (21.0)	40.2 (23.4)	36.1 (23.6)	< 0.0001	41.5 (18.9)
WOMAC stiffness	69.7 (16.3)	58.5 (18.3)	44.1 (26.0)	37.0 (25.1)	< 0.0001	48.6 (20.1)
WOMAC function	66.0 (19.4)	53.2 (20.3)	41.1 (25.8)	39.2 (25.1)	< 0.0001	46.6 (21.3)

Mean (standard deviation) for Western Ontario and McMaster University Osteoarthritis Index (WOMAC) subscales over 22 weeks in 20 patients with inflammatory osteoarthritis of the knee who received open-label adalimumab for 12 weeks. ^aWeek 12 data versus baseline according to paired t test using last-observation-carried-forward data. ^bWeek 22 data are based on 16 patients who attended for assessment.

ISSN: 1478-6362